Abbott Laboratories (ABT) Receivables - Net (2009 - 2026)

Abbott Laboratories has disclosed Receivables - Net across 18 years of filings, most recently posting $8.2 billion for Q1 2026.

• Receivables - Net for Q1 2026 came in at $8.2 billion, up 12.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.2 billion (up 12.05% YoY), and the FY2025 annual result was $7.9 billion, up 14.5% from the prior year.
• Receivables - Net came in at $8.2 billion for Q1 2026 at Abbott Laboratories, up from $7.9 billion in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $8.2 billion in Q1 2026 to a low of $6.0 billion in Q1 2023.
• The 5-year median for Receivables - Net is $6.9 billion (2024), against an average of $7.0 billion.
• Across the five-year window, Receivables - Net climbed 17.77% in 2022 and declined 16.14% in 2023, its largest moves.
• Abbott Laboratories' Receivables - Net stood at $6.2 billion in 2022, then increased by 5.58% to $6.6 billion in 2023, then grew by 5.48% to $6.9 billion in 2024, then advanced by 14.5% to $7.9 billion in 2025, then advanced by 3.54% to $8.2 billion in 2026.
• The last three Receivables - Net figures came in at $8.2 billion (Q1 2026), $7.9 billion (Q4 2025), and $8.1 billion (Q3 2025), per Business Quant data.